Abstract Number: 1392 • ACR Convergence 2020
Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Background/Purpose: Aminaphtone has been used for many years to treat microvascular disorders. In vitro Aminaphtone counteracts vasoconstriction downregulating endothelin-1 production and interferes with adhesion molecules…Abstract Number: 1396 • ACR Convergence 2020
Digital Artery Volume Index (Davix©) Predicts Onset of Future Digital Ulcers in Patients with Systemic Sclerosis
Background/Purpose: Neointima proliferation is a key pathologic feature of Systemic Sclerosis (SSc), causing arterial vessel narrowing. It is a recognised culprit pathological lesion in Digital…Abstract Number: 149 • 2019 ACR/ARP Annual Meeting
Teaching Rare Diseases Through Role Play: Results of an Experimental Workshop About Raynaud Phenomenon
Background/Purpose: Systemic autoimmune diseases are mostly taught through theoretical lectures, which do not allow for the acquisition of physical examination skills and semiologic confrontation. We…Abstract Number: 868 • 2019 ACR/ARP Annual Meeting
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the “Tamer”‘ Study
Background/Purpose: Statins have pleiotropic effects felt to influence in their beneficial cardiovascular effects. These include increased nitric oxide production and improved endothelial function, modulation of…Abstract Number: 1635 • 2019 ACR/ARP Annual Meeting
Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis
Background/Purpose: To evaluate any correlation between the Raynaud's Condition Score (RCS) and the morphological and functional methods available to evaluate microvascular damage in systemic sclerosis (SSc) patients (1-4). Methods: Sixty-six…Abstract Number: 2598 • 2019 ACR/ARP Annual Meeting
Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Background/Purpose: Aminaphtone treatment improves clinical symptoms of Raynaud's phenomenon (RP) and increases peripheral blood perfusion (BP) in patients with either primary or secondary RP (1-2).The…Abstract Number: 1730 • 2018 ACR/ARHP Annual Meeting
A Role for Duplex Ultrasound of Hand Arteries in the Assessment of the Vasculopathy Associated to Systemic Sclerosis-like Diseases
Background/Purpose: Small vessel arteriopathy precedes the development of organ damage and tissue fibrosis in systemic sclerosis (SSc) and related disorders. It is currently considered that…Abstract Number: 1879 • 2018 ACR/ARHP Annual Meeting
The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study
Background/Purpose: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of pulmonary arterial hypertension associated with connective tissue disease. It was anticipated that…Abstract Number: 2692 • 2018 ACR/ARHP Annual Meeting
High Frequency Ultrasound As a Novel Approach to Quantifying the Digital Microangiopathy of Systemic Sclerosis
Background/Purpose: Structural and functional vascular abnormalities occur in Systemic Sclerosis (SSc). We report on the use of High Frequency Ultrasound (HFUS) with Superb Microvascular Imaging…Abstract Number: 2701 • 2018 ACR/ARHP Annual Meeting
Botulinum Toxin in the Management of Raynaud’s Phenomenon
Background/Purpose: The objectives of this study were to evaluate the effectiveness and safety of botulinum toxin injection in Raynaud’s phenomenon. Methods: Medline and Embase databases…Abstract Number: 1704 • 2017 ACR/ARHP Annual Meeting
Non-Randomized Controlled Trial to Evaluate the Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis
Background/Purpose: Patients with systemic sclerosis (SSc) often display Raynaud’s phenomenon, which causes digital skin ulcers. Since these ulcers are not associated with autoimmune factors, conventional…Abstract Number: 2096 • 2017 ACR/ARHP Annual Meeting
Nailfold Capillaroscopy Is an Opportunity for Telerheumatology
Background/Purpose: The 2013 classification criteria for systemic sclerosis (SSc) provide 2 points (towards a 9 point diagnosis) for patients who have abnormal capillaroscopy. In the…Abstract Number: 2168 • 2017 ACR/ARHP Annual Meeting
Dissociation of FVC and Dlco in Patients with Dermatomyositis and Polymyositis
Background/Purpose: Interstitial lung disease in patients with polymyositis (PM) and dermatomyositis (DM) is characterized by decrease in both lung compliance and pulmonary vascularity, leading to…Abstract Number: 2697 • 2017 ACR/ARHP Annual Meeting
Systemic Sclerosis Quality of Life Questionnaire (SScQoL) Captures the Complex Problems Experienced By Patients with Scleroderma
Background/Purpose: Systemic sclerosis (SSc) is a chronic rheumatic disease that disturbs the patients’ biological, social, emotional spiritual, and physical functioning; resulting in reduced quality of…Abstract Number: 2889 • 2017 ACR/ARHP Annual Meeting
Aminaphtone Ameliorates Clinical Symptoms and Increases Skin Blood Perfusion in Patients with Both Primary and Secondary Raynaud Phenomenon: A Six-Month Open Study
Background/Purpose: Current treatments for Raynaud's phenomenon (RP) have limited efficacy, which was mainly demonstrated by physician/patient reported outcomes. Aminaphtone is a vasoactive drug recently suggested…
- 1
- 2
- 3
- …
- 5
- Next Page »